Sign In
Buy RMD
$205.84
-13.91 (-6.33%)
At Close: Jul 08, 2026
ResMed Analyst Backs Portfolio Reset
02:03pm, Thursday, 09'th Jul 2026
ResMed Inc. (NYSE:RMD) agreed to sell its MatrixCare business on Tuesday to Frazier Healthcare Partners, a private equity firm focused exclusively on health care, for $490 million.
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
10:51am, Wednesday, 08'th Jul 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Top 50 High-Quality Dividend Growth Stocks For July 2026
07:42am, Wednesday, 08'th Jul 2026
I track a curated universe of 50 high-quality dividend growth stocks to identify opportune entry points based on valuation and future return potential. Year-to-date through June, the investable univer
ResMed to sell software business MatrixCare for $490 million
06:07pm, Tuesday, 07'th Jul 2026
ResMed said on Tuesday it would sell its software business MatrixCare to private equity firm Frazier Healthcare Partners for $490 million in cash, as the health technology company sharpens its f
Frazier Healthcare Partners Announces Definitive Agreement to Acquire MatrixCare
05:06pm, Tuesday, 07'th Jul 2026
SEATTLE--(BUSINESS WIRE)--Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on the healthcare industry, today announced it has entered into a definitive agreement to a
Resmed Announces Agreement to Sell MatrixCare Business
04:30pm, Tuesday, 07'th Jul 2026
SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ente
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Tuesday, 07'th Jul 2026
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?
11:40am, Tuesday, 07'th Jul 2026
ResMed (RMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down
Here's Why ResMed (RMD) is a Strong Growth Stock
10:45am, Tuesday, 07'th Jul 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ResMed (RMD) Upgraded to Buy: Here's Why
01:01pm, Wednesday, 01'st Jul 2026
ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think ResMed (RMD) Could Surge 28.21%: Read This Before Placing a Bet
10:55am, Wednesday, 01'st Jul 2026
The mean of analysts' price targets for ResMed (RMD) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
04:30pm, Tuesday, 30'th Jun 2026
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday,
ResMed: Fear-Driven Selloff Creates A Compelling Margin Of Safety Entry Point
05:18pm, Monday, 29'th Jun 2026
ResMed (RMD) exemplifies the razor-and-blade model, leveraging inevitability, brand loyalty, inexpensive recurring costs, and a superior user experience. RMD dominates the sleep apnea market with a 62
This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
09:13am, Wednesday, 17'th Jun 2026
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Futures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX) or SpaceX IPO rush is starting to fade somewhat.
